<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Goldberg, Anne Carol</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Taking on High-Density Lipoprotein Cholesterol and Triglycerides</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Dyslipidemia plays a critical role in cardiovascular (CV) risk. Strong evidence supports that lower low-density lipoprotein cholesterol is better, but there are more questions than answers on what to do about triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). This article discusses high TGs and HDL-C, emerging CV disease risk factors, as well as novel therapeutic strategies for plasma lipid disorders.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>